These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class. Hargreaves R; Olesen J Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659 [TBL] [Abstract][Full Text] [Related]
9. Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety. Singh A; Balasundaram MK Clin Drug Investig; 2022 Apr; 42(4):301-308. PubMed ID: 35230651 [TBL] [Abstract][Full Text] [Related]
10. C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system. Edvinsson JCA; Warfvinge K; Krause DN; Blixt FW; Sheykhzade M; Edvinsson L; Haanes KA J Headache Pain; 2019 Nov; 20(1):105. PubMed ID: 31718551 [TBL] [Abstract][Full Text] [Related]
11. Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries. Rubio-Beltran E; Chan KY; Danser AJ; MaassenVanDenBrink A; Edvinsson L Cephalalgia; 2020 Apr; 40(4):357-366. PubMed ID: 31674221 [TBL] [Abstract][Full Text] [Related]
12. Atogepant: First Approval. Deeks ED Drugs; 2022 Jan; 82(1):65-70. PubMed ID: 34813050 [TBL] [Abstract][Full Text] [Related]
13. Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats. Ma QP; Hill R; Sirinathsinghji D Eur J Neurosci; 2001 Jun; 13(11):2099-104. PubMed ID: 11422450 [TBL] [Abstract][Full Text] [Related]
15. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Levy D; Burstein R; Strassman AM Ann Neurol; 2005 Nov; 58(5):698-705. PubMed ID: 16240341 [TBL] [Abstract][Full Text] [Related]
16. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. Eftekhari S; Warfvinge K; Blixt FW; Edvinsson L J Pain; 2013 Nov; 14(11):1289-303. PubMed ID: 23958278 [TBL] [Abstract][Full Text] [Related]
17. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review. Dos Santos JBR; da Silva MRR Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493 [TBL] [Abstract][Full Text] [Related]
18. CSD-Induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP's Role in Migraine with Aura. Schain AJ; Melo-Carrillo A; Stratton J; Strassman AM; Burstein R J Neurosci; 2019 Jul; 39(30):6001-6011. PubMed ID: 31127003 [TBL] [Abstract][Full Text] [Related]
19. Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine. Kopruszinski CM; Thornton P; Arnold J; Newton P; Lowne D; Navratilova E; Swiokla J; Dodick DW; Dobson C; Gurrell I; Chessell IP; Porreca F Cephalalgia; 2020 Dec; 40(14):1535-1550. PubMed ID: 33131305 [TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Goadsby PJ; Dodick DW; Ailani J; Trugman JM; Finnegan M; Lu K; Szegedi A Lancet Neurol; 2020 Sep; 19(9):727-737. PubMed ID: 32822633 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]